/ / / Tab 3

Research Article

Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy

Table 3

Table indicating the altered CKD statuses of eGFR (CKD-EPI) changes at month 12 and month 24 according to the baseline eGFR (CKD-EPI) levels.


	eGFR (mL/min/1.73 m²)	12 months, n (%)			Total	value
	eGFR (mL/min/1.73 m²)	<60	60–89	≥90	Total	value

Baseline n (%)	<60	5 (38)	8 (62)	0 (0)	13 (100)	0.057
	60–89	1 (2)	46 (72)	17 (26)	64 (100)
	≥90	0 (0)	14 (27)	38 (73)	52 (100)
Total		6 (5)	68 (52)	55 (43)	129 (100)

	eGFR (mL/min/1.73 m²)	24 months, n (%)			Total	value
	eGFR (mL/min/1.73 m²)	<60	60–89	≥90	Total	value

Baseline n (%)	<60	2 (15)	11 (85)	0 (0)	13 (100)	0.006
	60–89	1 (2)	42 (65)	21 (33)	64 (100)
	≥90	0 (0)	13 (25)	39 (75)	52 (100)
Total		3 (2)	66 (51)	60 (47)	129 (100)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.